



Professor Barrie Kellam

Professor of Medicinal Chemistry, School of Pharmacy, University of Nottingham

Barrie originally graduated with a BPharm from the University of Nottingham in 1991 and, following his pre-registration training with Eli Lilly, returned to Nottingham to undertake his PhD in medicinal chemistry under the supervision of Prof Barrie Bycroft.

Postdoctoral research at the School of Pharmacy, University of London then led on to his appointment in 1997 as a lecture at Nottingham, with promotion to full Professor of Medicinal Chemistry in 2013. During this period, Barrie was the Director for Teaching and Learning in the School of Pharmacy (2007-2012) leading the development of the new MPharm programme delivered at Nottingham.

Barrie is a fellow of the Royal Pharmaceutical Society of Great Britain.

Barrie's research activities are primarily focused on the medicinal chemistry of G-Protein Coupled Receptors (GPCRs) and work within his group is currently focused on the beta-adrenoceptor, purinergic, orexin, histamine, Chemokine and opioid families. His research is also involved in the area of fluorescent ligand design and their implementation in high-throughput and high-content bioassays and single cell pharmacological measurement. This work also led to the grant of numerous patents culminating in the successful spinning out of the company CellAura Technologies Ltd which was acquired by HelloBio in 2014.